vimarsana.com
Home
Live Updates
Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma : vimarsana.com
Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma
Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.
Related Keywords
San Francisco
,
California
,
United States
,
Talquetamab Talvey
,
Helen Diller Family Comprehensive Cancer Center
,
Myeloma Program
,
University Of California
,
Ajai Chari
,
Multiple Myeloma Program
,
Diller Family Comprehensive Cancer
,
Talquetamab
,
Gprc5d Cd3 Bispecific Antibody
,
Phase 1 2 Monumental Studies
,
Relapsed Refractory Multiple Myeloma
,
2023 Ash Annual Meeting
,
Adverse Effects
,
vimarsana.com © 2020. All Rights Reserved.